Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests
- PMID: 32007541
- DOI: 10.1016/j.cgh.2020.01.029
Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests
Abstract
Background & aims: Screening colonoscopies are of uncertain benefit for persons with negative results from a fecal immunochemical test (FIT). We investigated detection of CRC by colonoscopy in asymptomatic, average-risk, FIT-negative subjects.
Methods: We conducted a retrospective, population-based cohort study of 96,804 subjects with an initial negative result from a FIT at ages 50-75 years, from 2008 through 2014, who then underwent colonoscopy, using the Kaiser Permanente California databases. We identified participants diagnosed with CRC from January 1, 2008 through December 31, 2015 from a cancer registry. Subjects were followed until initial colonoscopy, health plan disenrollment, death, or December 31, 2015. We reviewed records from 400 randomly selected persons without CRC (controls) for risk features to estimate the proportion who underwent screening colonoscopy. We performed logistic regression to identify variables associated with CRC detection.
Results: Of 257 subjects with a diagnosis of CRC, 102 did not have a record of CRC risk factors; 86 of these patients (84.3%) had non-advanced-stage CRC (no regional node spread/distant metastases). Of the 400 controls, 299 (74.75%; 95% CI, 70.49%-79.01%) lacked CRC risk features, enabling estimation that 72,263 (mean age, 57.5 ± 7.0 y; 54.5% female) had undergone screening colonoscopy. CRC was detected in 1.4 per 1000 persons after 1 FIT, without association with increasing FITs (P = .97). CRC was detected in 1.3 per 1000 persons in 2 y or less after the last FIT and in 4.4 per 1000 persons more than 2 y after the last FIT (P < .001). When the last FIT was 2 y earlier or less, CRC increased from 0.7 per 1000 persons age 50-59 y to 3.1 per 1000 persons older than 70 y. Age and time from the last FIT were associated with CRC, with adjusted odds ratios of 1.08 (95% CI, 1.05-1.11) and 2.76 (95% CI, 1.28-5.95), respectively.
Conclusions: In asymptomatic, average-risk persons with a negative result from a FIT, CRC is infrequent within 2 y after the last FIT (especially for persons younger than 60 y), usually non-advanced, and unrelated to the number of FITs performed.
Keywords: Colon Cancer; Diagnostic; Incidence; Risk Factors.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Do We Need a New Paradigm for Assessing the Accuracy of Fecal Immunochemical Test Screening?Clin Gastroenterol Hepatol. 2020 Dec;18(13):2873-2875. doi: 10.1016/j.cgh.2020.04.008. Epub 2020 Apr 11. Clin Gastroenterol Hepatol. 2020. PMID: 32289539 No abstract available.
Similar articles
-
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483499
-
Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.Clin Gastroenterol Hepatol. 2020 Mar;18(3):667-675.e1. doi: 10.1016/j.cgh.2019.08.015. Epub 2019 Aug 13. Clin Gastroenterol Hepatol. 2020. PMID: 31419575 Clinical Trial.
-
Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.Clin Gastroenterol Hepatol. 2020 Jun;18(7):1493-1500. doi: 10.1016/j.cgh.2019.08.021. Epub 2019 Aug 20. Clin Gastroenterol Hepatol. 2020. PMID: 31442598
-
Screening for Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. Report No.: 20-05271-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 May. Report No.: 20-05271-EF-1. PMID: 34097369 Free Books & Documents. Review.
-
Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jun. Report No.: 14-05203-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jun. Report No.: 14-05203-EF-1. PMID: 27441328 Free Books & Documents. Review.
Cited by
-
Postponing colonoscopy for 6 months in high-risk population increases colorectal cancer detection in China.Cancer Med. 2023 May;12(10):11816-11827. doi: 10.1002/cam4.5850. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36951442 Free PMC article.
-
Reusing a prepaid health plan's fecal immunochemical tests for microbiome associations with colorectal adenoma.Sci Rep. 2022 Aug 31;12(1):14801. doi: 10.1038/s41598-022-18870-w. Sci Rep. 2022. PMID: 36045142 Free PMC article.
-
The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients.J Clin Lab Anal. 2022 Jul;36(7):e24572. doi: 10.1002/jcla.24572. Epub 2022 Jun 23. J Clin Lab Anal. 2022. PMID: 35735582 Free PMC article.
-
Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer.iScience. 2022 Apr 4;25(5):104203. doi: 10.1016/j.isci.2022.104203. eCollection 2022 May 20. iScience. 2022. PMID: 35479401 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
